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ABSTRACT
A New Method in Subjective Tinnitus Management:
The Use of a Nutraceutical Formulation to Improve Patient Outcomes

by

Jade H. Faulkner

Advisor: Dorothy Neave-DiToro, Au.D., CCC-A, FAAA

Objective: This project aims to implement an evidence-based clinical practice guideline at the
International Hearing Centre (IHC) in Lagos, Nigeria for future research and data collection of
their subjective tinnitus management using a nutraceutical formulation called ‘NHANCED
Hearing (NH). After learning the IHC had incomplete charting in regard to tinnitus
questionnaires pre- and post-administration of the NH formula, this capstone project sought to
apply evidence-based guidelines for proper diagnostic evaluations and charting to assist in future
research of the NH formula.
Methodology: A review and synthesis of current clinical practice guidelines in the United
States, Germany, the Netherlands, Sweden, Denmark, and Japan allowed this research to present
a complete diagnostic evaluation template and suggested timelines for administering subjective
measures of tinnitus disturbance. Future research with IHC will benefit from complete charting
for a retrospective chart review including tinnitus-specific case history, audiologic pure tone
thresholds, tympanometry and acoustic reflex thresholds, distortion product otoacoustic
emissions, and completed Tinnitus Handicap Inventory (THI) administered at 3-month intervals.
Results: Future research will be analyzed for clinically significant changes (p<0.05) in tinnitus
disturbance as measured by the THI at baseline and 1-year post-initial administration. A roadmap
for statistical analysis of the data is included in this project.
Discussion: Anecdotal reports from clinicians at the IHC suggest significant improvements in
subjective tinnitus as per patients taking the NH formulation. A proper, evidence-based,
framework for implementing and measuring subjective improvement in tinnitus percept is
necessary for future research. In addition to subjective reports, the distance traveled and cost out
of pocket for the nutraceutical reveal a strong indication of perceived benefit.
Conclusion: The goal of this project is to implement an evidence-based clinical protocol at the
IHC to standardize patient care in order to evaluate and statistically analyze the efficacy of the
NH formulation on subjective tinnitus sufferers in the future. Future research can use this project
as a template to assess changes to tinnitus percept in patients taking the NH formulation.
Key words: audiology, tinnitus, antioxidants, nutraceutical, clinical practice guideline,
subjective tinnitus, bothersome tinnitus
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INTRODUCTION
Tinnitus and Hearing Loss
Tinnitus is the conscious perception of an auditory sensation in the absence of a
corresponding external stimulus (Baguley, McFerran, and Hall, 2013). Patients with tinnitus are
heterogeneous in tinnitus experience. For example, tinnitus may be subjective or objective, highpitched or low-pitched, ringing or hissing, or have other varied clinical presentations. According
to the American Tinnitus Association (n.d.), subjective tinnitus, experienced by 99% of tinnitus
sufferers, is the most common type and perceived by the patient only. Meanwhile objective
tinnitus, experienced by about 1% of patients, can be perceived by the clinician by auscultation
(American Tinnitus Association, n.d.). Generally, objective tinnitus comes in the form of
pulsatile tinnitus, imitating the heartbeat (Baguley, McFerran, and Hall, 2013).
Risk factors for tinnitus are vast, adding to its heterogeneity. Hearing loss is the main
risk factor for tinnitus, even though there are patients that present with tinnitus and normal
audiometric data or others with hearing loss not reporting tinnitus (Baguley, McFerran, and Hall,
2013). Other factors Baguley et al. (2013) offer: environmental factors, such as noise exposure;
medicinal factors including over-the-counter and prescription drugs that can be harmful to the
ear and hearing, known as ototoxic drugs, including corticosteroids, loop diuretics, platinum
based chemotherapy agents, and non-steroidal anti-inflammatory drugs (NSAIDs); and lastly
pathologies of the ear such as otitis media, labyrinthitis, acoustic neuroma, Meniere’s disease,
and otosclerosis are often accompanied by tinnitus. Thus, an unknown pathogenesis in addition
to a plethora of presentations, lead to a very difficult to manage chronic disability. Interestingly,
according to Hobson, Chisholm, and El Refaie (2012), in 60% of patients that have had the
auditory nerve severed secondary to tumor removal in acoustic neuroma, the presence of tinnitus
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remained, suggesting “the fundamental importance of the central auditory pathways in the
maintenance of the symptom, irrespective of the initial mode of generation being the cochlea or
the vestibulo-cochlear nerve” (pg. 3).
Severity is highly variable across tinnitus sufferers. The research has shown no
significant correlation between severity and the degree of hearing loss, nor has there been a
correlation between the loudness of the tinnitus and how bothersome it is to the
patient. Depression, however, is highly correlated with the severity of tinnitus (Udupi et al.,
2013). The disability generated by tinnitus depends “on primary psychological factors, such as
difficulty in dealing with the problem” (Pinto et al., 2010, pg. 21). The severity of annoyance
due to tinnitus and the presence of psychiatric conditions is highly correlated as well. Most
researchers agree, 10-15% of the population is affected by some form of tinnitus, and most are
able to habituate to the sensation (Celik & Koyuncu, 2018; Ciorba et al., 2013). Researchers,
however, do not agree on the number of tinnitus sufferers unable to habituate to the sound which
has been shown to lead to increased anxiety, social isolation, and depression. This population is
reportedly between 0.5% and 20% of patients (Baguley et al., 2013; Celik & Koyuncu, 2018;
Pinto et al., 2010). Trevis, McLachlan, and Wilson (2018) reviewed the psychological effects in
chronic tinnitus sufferers unable to adjust to the sensation. The systematic review analyzed
chronic tinnitus and its effect on emotional well-being (i.e. quality of life, depression and
anxiety) and cognitive functioning. Chronic tinnitus sufferers were found to have a clinically
significant increase in depression and anxiety symptoms compared to healthy controls. Some of
the most notable impacts of tinnitus include poor sleep, social withdrawal, interference with
work, suicidal thoughts, confusion, and worry (Trevis, McLachlan, and Wilson, 2016).
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Anatomy and Physiology of the Ear & Oxidative Stress
The ear is divided into three anatomic parts: outer, middle, and inner. The outer ear
includes the external, visible part of the ear, known as the pinna, and the ear canal. The middle
ear begins at the tympanic membrane, or ear drum, and houses the ossicles, or bones of the ear,
the malleus, incus, and stapes. Together, the outer and middle ear “form the sound conducting
mechanism” (Alberti, 2001, p. 54). The pinna collects sound and channels it into the ear
canal. The sound is then directed to the tympanic membrane, causing vibration and movement
of the ossicles. The inner ear “consists of the cochlea which transduces vibration to a nervous
impulse and the vestibular labyrinth which houses the organ of balance” (p. 54). The cochlea is
“a bony tube filled with perilymph in which floats the endolymph filled membranous labyrinth”
(p. 56). The footplate of the stapes, in the middle ear, sits in the oval window of the cochlea.
Vibration of the stapes footplate “vibrates the perilymph in the cochlea” (p. 56). The basilar
membrane, one of the separating structures between the perilymphatic and endolymphatic spaces
in the cochlea, “responds resonantly to highest frequencies at its basal end nearest the oval
window and to progressively lower frequencies” at its apical end, furthest from the oval window
(p. 58). “Four rows of hair cells lie on top of the basilar membrane, together with supporting
cells”: One row of inner hair cells (IHCs) and three rows of outer hair cells (OHCs). It has “an
abundant nerve supply carrying messages to and from the brain” (p. 57). Therefore, vibration of
the perilymph by the stapes footplate in the oval window is transmitted into a nervous impulse
carried along the eighth cranial nerve, the vestibulocochlear nerve, “from the cochlea to the
brainstem. Here the nerve fibers reach nuclei where they relay with other nerve fibers…The
fibers pass up the hindbrain to the midbrain and the cerebral cortex” (p. 58, 61). “Any sound
introduced at the oval window, by motion of the stapes, is transmitted along the basilar
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membrane as a traveling wave until all of its frequency components reach their respective place
of resonance where they stop and travel no further” (p. 60). The inner and outer hair cells play a
pivotal role in sound perception and transmission. Damage to the cochlea via noise exposure or
ototoxic medication, for example, will result in death of OHCs that are not regenerative. “If the
OHCs are damaged, they no longer contract in response to slight sounds and the IHCs are not
stimulated…producing a hearing loss for low intensity sounds” (p. 61).
As previously indicated, the pathogenesis of tinnitus is not yet clearly defined. In most
patients, the development of tinnitus can be linked to damage to the cochlea. Neri et al. (2006)
evaluated the oxidative stress of 44 patients with idiopathic tinnitus and 25 healthy volunteers.
They reported patients with idiopathic tinnitus presented a significant increment (p<0.05) of
oxidative damage marker concentrations and plasma scavenger activity in jugular blood,
accompanied by increased free radical concentrations. Based on these findings, they concluded
that oxidative stress is important in the pathogenesis of tinnitus.
According to Pham-Huy, He, and Pham-Huy (2008), free radicals, or unpaired electrons,
are highly reactive and are generated through the use of oxygen in the metabolism of certain
compounds in the body’s daily processes. Excessive production of free radicals can damage
normal cells. Environmental factors, including stress, smoke and pollution, and elevated iron
and copper in the body can contribute to the creation of free radicals at an increased rate. This
excessive production causes oxidative stress, an inflammation to the cells that causes damage to
DNA, RNA, cell membranes, proteins, and lipids.
Koc et al. (2016) further explain reactive oxygen species (ROS) play a role in the
pathogenesis of otlogic and neurologic diseases. High concentrations of ROS can have cytotoxic
and neurotoxic effects, resulting in damage to the auditory hair cells of the labyrinth and the
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acoustic system. Then, as Ciorba et al. (2013) suggest, it is reasonable to suppose “antioxidant
drugs can reduce the amount of intracellular damages mediated by ROS” (p. 249). The role of
oxidative stress in certain inner ear disorders, such as Meniere's disease, noise-induced hearing
loss, labyrinthitis, cisplatin ototoxicity and aminoglycoside ototoxicity is well known (Calabrese
et al., 2010; Fujimoto and Yamasoba, 2014; Haase et al., 2016; Koc et al., 2016). According to
Haase et al. (2016), biochemical pathways are increasingly becoming the culprit for
abnormalities “from the cortical level through the inner ear apparatus” (p. 56). By understanding
the effects of oxidative stress and free radicals on the inner ear, new biological options may be
proposed in the management of tinnitus, especially for patients debilitated by the symptoms.

Tinnitus Management
Over the years, the research has shown inconsistent findings validating the efficacy of
over-the-counter (OTC) vitamins, minerals, and supplements for the reduction of
tinnitus. Antioxidant therapies have included phospholipids, vitamins C and E, Ginkgo biloba,
alpha lipoic acid, zinc, garlic, and lemon-bioflavonoid, among others (DiSogra, 2010). The
myriad clinical management strategies in attempts to alleviate tinnitus symptoms have ranged
from “education and advice, relaxation therapy, tinnitus retraining therapy (TRT), cognitive
behavioral therapy (CBT), sound enrichment using ear-level sound generators or hearing aids,
and drug therapies to manage comorbid symptoms like insomnia, anxiety and depression”
(Person et al., 2016, pg. 6).
Drug therapies such as tricyclic antidepressants and serotonin-reuptake inhibitors have
not been shown to reduce the tinnitus loudness or perception, but they have had a positive role in
improving psychological distress (Baguley, McFerran, Hall, 2013). According to Pirodda,
Raimondi, and Ferri (2010), melatonin, used with patients suffering from tinnitus-related
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insomnia, improves sleep even though the effect on tinnitus severity is minimal. Increased
intake of dietary components such as vitamin B, zinc, and magnesium have had poor quality of
evidence and have been contradictory. For example, Savastano et al. (2007) and Gopal et al.
(2015) both reported positive findings. Savastano et al. (2007) reported a decrease in reactive
oxygen species (ROS) and tinnitus disturbance after 18 weeks of oral treatment with
phospholipids and vitamins in a cohort of 31 patients reporting idiopathic tinnitus. They
analyzed measured changes in tinnitus loudness matching and subjective disturbance using the
visual analogue scale (VAS). Savastano et al. concluded patients experienced a decrease in ROS
and tinnitus loudness and disturbance at the end of the trial (2007). Gopal et al. (2015) found not
only a subjective improvement in tinnitus distress in a case study of a female taking acetyl Lcarnitine (ALCAR) for thirty days, but they also noted improved post-treatment audiologic
thresholds and a clinically significant decrease in tinnitus questionnaire scores on the THI, 14
points pre-treatment to 4 points post-treatment. On the other hand, Polanski et al. (2016) found
no significant difference in pre- and 6-month post-treatment tinnitus questionnaires within
subjects, nor between subjects in their four groups of patients taking either (1) Ginkgo biloba, (2)
vitamin C with alpha lipoic acid, (3) papaverine hydrochloride with vitamin E, or (4) the placebo
group.
The door for research is open in the use of antioxidant approaches to relieving tinnitus
distress in patients. Although current research is still undecided on when and how to implement
antioxidant therapy, there is strong data revealing a link between tinnitus and oxidative stress
(Ciorba et al., 2013; Haase et al., 2011; Koc et al., 2016; Koca et al., 2018). According to PhamHuy et al. (2008), oxidative stress can be counteracted naturally by antioxidants produced in the
body, “endogenous antioxidants,” or it can be supplied through foods and supplements,
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“exogenous antioxidants” (p. 92). They state: “The roles of antioxidants are to neutralize the
excess of free radicals, to protect the cells against their toxic effects and to contribute to disease
prevention” (p. 92).
Reactive oxygen species (ROS), as described previously, in large amounts can be
hazardous to the body causing pathological disease (Pawlak-Osinska et al., 2018). ROS are
formed in the cochlear hair cells after exposure to cisplatin, aminoglycosides, salicylates, and
noise, for example. However, if in a homeostatic state, ROS are essential to body function,
specifically in signal transmission inside the cell. Endogenous antioxidants produced by the
body, such as catalase, glutathione peroxidase, and glutathione S-transferase, can help to balance
ROS activity. An imbalance between ROS and endogenous antioxidants leads to pathological
disease, including, but not limited to, damage to the inner ear like hearing loss and
tinnitus. Interestingly, in the Pawlak-Osinska et al. study (2018), the tinnitus subjects showed
significantly lower levels of the endogenous antioxidants glutathione peroxidase and erythrocyte
glutathione than the control group (p=0.026 and p=0.00, respectively).
Antioxidants obtained by food sources are known as exogenous antioxidants.
Devasagayam et al. (2004) provide a comprehensive list of fruits, vegetables, legumes, oils, dairy
products, and more that provide antioxidant support for flavonoids, polyphenols, carotenoids,
and vitamins. Haase et al. (2011) suggest preventive and protective benefits of antioxidants such
as vitamin E, α-Lipoic acid, Coenzyme Q10, vitamin C and magnesium. They further assert the
combination of multiple antioxidants prevents the possibility of creating more free radicals in the
body. Haase et al. reminds us that although single agents may provide some benefit, more likely,
the oxidation of an antioxidant creates free radicals (2011).
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Two therapies used in managing tinnitus are cognitive behavioral therapy (CBT) and
tinnitus retraining therapy (TRT). CBT aims to alter the patient’s response to tinnitus, not the
volume or perception. Jun and Park (2013) explain the concept of CBT is to correct the negative
perception, thoughts, and beliefs about the tinnitus, and replace them with “positive and realistic
thoughts” (p. 101). CBT does not aim to reduce the acoustic features of the tinnitus, rather the
distress and handicap induced by the tinnitus. TRT, on the other hand, uses a two-step process to
reduce the perception, emotional associations, and negative reactions to the tinnitus. Step one,
described by Formby and Scherer (2013), involves “directive counseling,” similar to CBT, to
“initiate the habituation process by neutralizing the negative and emotional reactions to the
tinnitus” (p. 135). Step two, they continue, involves the use of ear-level sound generators to
enrich the sound environment and decrease the difference between the level of the tinnitus and
the level of the ambient environmental sounds.
Sound therapy, in its various forms, has been used in attempts to reduce tinnitus distress
in chronic tinnitus patients. According to Baguley, McFerran, and Hall (2013), after a treatable
pathology associated with tinnitus has been excluded, such as cerumen or infection, standard
care is to give an explanation of the situation, followed by sound therapy and intervention to
reduce the distress. Sound therapy includes hearing aids or sound generators to effectively mask
the tinnitus. In a systematic review by Hobson, Chisholm, El Refaie (2012), six trials of sound
therapy masking studied 553 participants. Hobson et al. found the studies failed to show strong
evidence of the efficacy of sound therapy in changing the loudness or overall severity of tinnitus;
however, some studies showed sound therapy devices were subjectively helpful in reducing
levels of tinnitus annoyance and improved scores on questionnaires like the TRQ
(2012). Baguley et al. (2013) also discuss emerging sound treatments that not only mask

8

perception of the tinnitus, but are also effective as a therapeutic relaxant like the Widex Zen
program, or one that reduces emotional arousal like the Neuromonics device (see also Tyler et
al., 2017; Hanley et al., 2008). At present, the evidence is still inconclusive on sound therapy as
a tool to eliminate the perception of tinnitus; however, outcomes are strong for reducing its
perception when in use.
‘NHANCED Hearing Nutraceutical Formulation
The current study aims to delve into an antioxidant micronutrient formulation created by
Dr. Gerald Haase of the New Age Beverages Corporation, and formerly of the Premier
Micronutrient Corporation (PMC). The ‘NHANCED Hearing (NH), formerly Hearing Health
(HH), formula claims to decrease the amount of free radicals in the body to increase effective
immune function. This NH formula includes Vitamins A, C, D, E, B , B , Calcium, Zinc,
6
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Magnesium, and other vitamins and antioxidants. It is referred to as a nutraceutical, defined by
Gupta et al. (2010) as a product that is derived from food sources with extra health benefits in
addition to the basic nutritional value found in foods. Gupta et al. (2010) elaborate:
“Nutraceuticals are non-specific biological therapies used to promote general well-being, control
symptoms, and prevent malignant processes” (p. 56). The difference between a nutraceutical and
the average over-the-counter (OTC) antioxidants is the specific and deliberate formulation that
has an exact dosing schedule for best patient outcomes (Jain and Ramawat, 2013).
The NH nutraceutical was created and marketed to preserve hearing status and combat
free radicals in the hearing organ on a cellular level. Dr. Gerald Haase, creator of the NH
formula, worked closely with the United States Military, Department of Defense, and NASA on
the nutraceutical. According to Haase (2014), PMC formulations help reduce the amount of free
radicals and inflammation, thereby increasing the immune system function. In a 2011
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publication, Haase posits a proper “combination of antioxidant supplementation may improve
efficacy of standard therapy for some hearing disorders” (p. 57). Singular antioxidants have their
own positive properties for improving immune and hearing function; however, he notes, “single
agents [antioxidants], when oxidized, act as a free radical” (p. 57), meaning, in an attempt to
mitigate oxidative stress, one may be causing oxidative stress. An important factor in the
efficacy of the micronutrient is its specific and exacting dosing schedule. Haase (2011)
elaborates: “great fluctuations in antioxidant levels associated with only once a day or every
other day dosing” may not be consistent enough to be effective (p. 57). Therefore, “twice a day
dosing maintains more constant levels to increase biologic effectiveness, protect the genetic
machinery of the cell, and decrease cellular stress” (p. 57). The pilot study for Hearing Health
(now ‘NHANCED Hearing) revealed 7 patients out of 11 experienced a “clinically significant
reduction in tinnitus grade,” monitored by scores on the Tinnitus Handicap Inventory, pre- and
post-treatment (p. 59).
Measuring Tinnitus: Questionnaires
Baguley, McFerran and Hall (2013) point out since there is no objective test available for
most tinnitus patients, except in the case of pulsatile tinnitus which can be detected by
auscultation, other measures must be used to note changes in tinnitus perception and effects on a
patient’s well-being. They expand: Tests to match pitch and loudness of the tinnitus are difficult,
relate poorly to the patient’s distress, and offer little to the subsequent management plan. These
perceptual measurements of tinnitus do not reflect how bothered the patient is. Additionally,
there is no linear relationship between the intensity of the tinnitus and how bothered the patient is
by its perception; therefore, a self-report questionnaire will be the most effective tool for the
current study.
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Handicap from tinnitus can present as any or all of the following: Stress, anxiety,
depression, insomnia, concentration difficulty, and quality of life impairments (Baguley, et al.,
2013). Questionnaires are generally used to assess the degree to which the patient is bothered
and handicapped from the tinnitus (Fackrell and Hoare, 2014). Questionnaires also help to
quantify and measure changes longitudinally. Improved scores on a tinnitus questionnaire can be
used as a counseling method to show the patient how a management technique is working over
time.
There are many tinnitus questionnaires available, but they do not all measure the same
aspects of the patient’s complaints (Fackrell and Hoare, 2014). The six most common
questionnaires are described here:
1. Tinnitus Questionnaire (TQ) – created by Hallam, Jakes, and Hinchcliffe. Fackrell and
Hoare (2014) explain, this validated 52-item questionnaire measures tinnitus severity
change and the relationship between different aspects of complaints and other
psychological variables. Answers are based on a 3-point scale of true, not true, or partly
true. The negative features of the TQ are the high demand on time; the majority of
questions focus on emotional and cognitive aspects of the handicap; the three-point scale
makes it difficult to notice small changes, and there is no grading system or minimal
clinically important change score. The Mini-TQ is a 12-question rapid version of the TQ.
It shows greater treatment effects than indicated with the TQ. The Mini-TQ also shows
high item-total correlations, reliability and sensitivity to change.
2. Tinnitus Handicap Questionnaire (THQ) -- Fackrell and Hoare (2014) continue, the THQ
is a validated 27-item questionnaire that is sensitive to change in handicap over
time. The answers are on a scale of 1-100 allowing patients to see small changes in
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handicap, making the THQ a sensitive outcome measure. However, no grading scale has
been developed and almost half of all statements relate to the psychological and
emotional aspects of tinnitus handicap.
3. Tinnitus Reaction Questionnaire (TRQ) -- Described by Fackrell and Hoare (2014) as a
validated 26-item questionnaire that was developed to assess the effects of psychological
distress on tinnitus and distinguish between its levels. The TRQ lacks a recommended
grading system or minimal clinically important change score. However, the five-point
Likert scale makes it more sensitive than the THI or TQ. The TRQ measures similar
constructs to those measured by more general questionnaires measuring depression or
anxiety, making it an important tinnitus assessor due to the psychological effects it has on
patients.
4. Tinnitus Handicap Inventory (THI) – Fackrell and Hoare (2014) explain the THI was
originally designed as a companion to the Hearing Handicap Inventory (HHI) and
Dizziness Handicap Inventory (DHI) to complete a set of tools to quantify perceived
handicap in a variety of hearing related conditions. This validated 25-item questionnaire
measures the impact of tinnitus on everyday function using a three-point scale, yes,
sometimes, or no. In contrast to some other tinnitus questionnaires, the THI has a
grading system categorizing tinnitus handicap based on the patient’s responses: slight,
mild, moderate, severe, or catastrophic. Additionally, a minimal clinically important
change score of 7 points has been determined to measure treatment related changes.
Similar to other tinnitus questionnaires, the THI focuses on the psychological and
emotional aspects of the handicap.
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5. Tinnitus Functional Index (TFI) – Fackrell and Hoare describe this 25-item questionnaire
that discriminates between levels of distress, and provides a responsive measure of
treatment related change. The answers are on a scale of 0-10, which allows for the
detection of small changes over time. Like the THI, the TFI has a grading system and a
minimal clinically important change score. Additionally, the questions in the TFI are
more evenly weighted across different aspects of tinnitus handicap than in other
questionnaires.
6. Self-efficacy for Tinnitus Management Questionnaire (SETMQ) – Smith and Fagelson
(2011) describe this 40-item questionnaire that allows patients to rate their answers on a
percentage scale from 0-100% in intervals of 10 percentage points. The questionnaire
rates the patient’s self-efficacy in various areas of tinnitus management. The areas
include routine tinnitus management, emotional response to tinnitus, internal thoughts
and interaction with others, tinnitus concepts, and use of assistive devices.

Tinnitus Management – An International Review
Fuller et al. (2017) performed a systematic review of current clinical guidelines for
tinnitus in Denmark, Sweden, Germany, the Netherlands, and the United States. The review
discusses both assessment guidelines across the countries and management guidelines. Fairly
consistently, the guidelines suggest physical examination by an otolaryngologist or other related
professional and a hearing examination which includes the complete audiologic evaluation
(CAE). Some guidelines suggest other audiologic assessments like auditory brainstem response
(ABR), loudness discomfort levels (LDL), and otoacoustic emissions (OAE), though these are
not consistent across countries. A tinnitus questionnaire is always indicated, regardless of
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country. The most popular questionnaires, according to the guidelines, are the THI and
TQ. Also, a psychological assessment is indicated, to include investigations of how the tinnitus
is affecting the patient’s daily life and comorbid symptoms.
The tinnitus management recommendations similarly remain consistent across countries
(Fuller et al., 2017). No medical treatments are indicated for tinnitus specifically; however,
recommendations are present for comorbidities, like depression, sleep, or anxiety. Audiological
interventions strongly recommend the use of hearing aids for tinnitus patients with hearing loss,
while TRT is recommended as a sound therapy for patients without hearing loss in all guidelines
except in Germany. Lastly, CBT is strongly recommended as a psychological therapy across the
board.
Ogawa et al. (2019) released clinical practice guidelines for diagnosis and treatment of
chronic tinnitus following the guidelines set forth in Fuller et al. (2017). They recommend the
use of a validated tinnitus questionnaire, namely the THI which has been translated into
Japanese, pure tone audiometry, pitch matching, and loudness balance testing. Imaging is
recommended by Ogawa et al., particularly for patients suffering from unilateral or pulsatile
tinnitus. Lastly, the Japanese guideline supports TRT and CBT as treatment and management
techniques for chronic tinnitus. A disadvantage for CBT at this time in Japan is the minimal
number of facilities offering CBT with trained experts, but they find it to be a cost-effective
treatment with no side effects.
Tunkel et al. (2014) created a comprehensive clinical practice guideline for the American
Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF). The
audiologic test battery recommended includes pure tone air conduction thresholds 250Hz
through 8000Hz including interoctave frequencies as deemed necessary by the clinician, bone
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conduction thresholds 250-4000Hz, speech recognition thresholds, word recognition scores,
immittance measures to include contralateral acoustic reflex thresholds (ARTs) 500-4000Hz,
ipsilateral ARTs 500-4000Hz, and acoustic reflex decay at 500 and 1000Hz. Tunkel et al.,
similar to Ogawa et al. (2019), recommend sound therapy and CBT for patients with persistent,
bothersome tinnitus. On the other hand, Tunkel et al. strongly advise against the use of dietary
supplements including Ginkgo biloba, melatonin, zinc, or other supplements for patients with
persistent, bothersome tinnitus. The authors report a lack of proven efficacy in randomized
clinical trials.
The Tinnitus Research Initiative (TRI) provides a broad flow-chart for clinical use to
assist in managing the chronic tinnitus patient (Biesinger et al., 2011). The guideline proposes
not only the case history and audiologic test battery, but it suggests psychoacoustic measures
including pitch matching, loudness matching, minimum masking levels, residual inhibition, and
loudness discomfort/growth tests. Although the current research project has determined
psychoacoustic measures to be difficult and poorly related to patient’s distress, the TRI considers
the psychoacoustic measures may offer diagnostic value in the counseling process for the chronic
tinnitus patient (Baguley et al., 2013; Biesinger et al., 2011). Additionally, psychoacoustic
measures may also aid in hearing device programming, specifically the loudness discomfort
levels.
In all, the above guidelines for tinnitus management are important for developed and
developing countries to implement for tinnitus patients. The current project proposes the
adoption of recommendations to better manage tinnitus patients, especially those with
bothersome tinnitus. Most importantly, the assessment of tinnitus patients must include a CAE,
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tinnitus questionnaire and examination by an otolaryngologist. The management, as proposed by
the current study, will include dispensing of the NH nutraceutical formulation.
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METHODOLOGY
The aim of this research project will be to measure the subjective changes in tinnitus
perception while using the NH nutraceutical. As seen in the literature review, the THI and TFI
are the only tinnitus questionnaires that have a grading system and minimal clinically important
change score; however, the TFI, according to Fackrell and Hoare (2014), has not undergone
formal validation. Therefore, changes will be measured by comparing the responses to the
Tinnitus Handicap Inventory (THI) at baseline, then in 3 month intervals at 3-, 6-, and 9-months’
post-administration, and 1-year post-administration. This will make it possible for researchers to
note changes in tinnitus perception and the level of distress for patients at periodic follow-up
appointments. The research hypothesizes using the NH formula will decrease the perception of
subjective tinnitus. Furthermore, the research will analyze if any change in tinnitus perception
remains over an extended period of time, for example a 6-month or 1-year period, and if
cessation of the nutraceutical has any positive or negative effects on the percept.
The study will be designed as a retrospective chart review. Data will be collected from
the International Hearing Centre (IHC) in Lagos, Nigeria. Anecdotal evidence from
Audiologists and Pharmacists at the IHC suggest improvements in subjective tinnitus severity as
per patient report, therefore, the research will examine the charts of patients to whom the
nutraceutical has already been administered. Data collected will be redacted patient files
containing only the following information: Gender, age, audiometric data including type and
degree of hearing loss, if any, description and duration of the tinnitus, the case history related to
hearing and tinnitus, and a pre- and post-administration tinnitus handicap inventory (THI)
questionnaire. A minimum of 30 patient charts will be reviewed in order to make statistically
significant claims of correlative effects of the nutraceutical formulation on subjective tinnitus
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perception. In light of the within-subjects design of the study, gender and age will not be
controlled for in data collection. Furthermore, there are discrepancies in the literature whether
gender or age have a significant effect on tinnitus. Seydel et al. (2011) found women to be more
emotionally affected by tinnitus using the Tinnitus Questionnaire (TQ) and four other
questionnaires investigating perceived stress, coping, and sense of coherence measures.
Regardless of age, Seydel et al. found women to have less loud tinnitus, compared to their male
counterparts, measured by tinnitus loudness matching (2011). The study found age and gender
to be important factors in psychometric outcomes. On the other hand, Udupi et al. (2013)
reported no significant differences between gender or age and tinnitus severity. The authors
found correlation between depressive symptoms and tinnitus severity, as has been previously
discussed.
The NH formula composition is seen below in Table 1. According to the specified
dosing schedule, patients are advised to take two pills, two times daily. This, as suggested by Dr.
Haase, will maintain antioxidant levels in the blood for increased efficacy and decreased cellular
stress (2011). The dosage will remain constant, with no tapering instructions.

Table 1. List of ingredients New Age Beverages Corporation NH Formula.
Ingredient

Amount Per
Serving

% Daily
Value

Vitamin A

5500 IU

183%

Vitamin C

250 mg

278%

Vitamin D

200 IU

25%

Vitamin E

200 IU

935%

Thiamin

4 mg

333%

Riboflavin

5 mg

385%
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Niacin

30 mg

188%

Vitamin B6

5 mg

294%

Folic Acid

200 mcg

50%

Vitamin B12

10 mcg

417%

Biotin

200 mcg

667%

Pantothenic Acid

10 mg

200%

Calcium

60 mg

5%

Magnesium

100 mg

24%

Zinc

15 mg

136%

Selenium

100 mcg

182%

Chromium

50 mcg

143%

Proprietary Blend – L-Cystine, L-Carnitine, Alpha Lipoic
Acid, Co-Enzyme Q10

575 mg

Unspecified

Inclusion criteria for patient data will include healthy adults age 18 and above. Since
tinnitus can affect both normal hearing and hearing impaired patients, the audiometric criteria
will be inclusive of both. In order to be a candidate, the patient must have a history of chronic
tinnitus lasting 6 months or longer. Although it has been established that tinnitus symptoms are
heterogeneous in presentation and percept, the research will be inclusive of the following
percepts: “ringing,” “buzzing,” “hissing,” “crickets,” “roaring.” The patient must be taking the
nutraceutical formulation for 3 months or longer, as recommended. The dosing schedule is
specific and imperative to follow; therefore, patients who have not taken two pills, twice daily,
will be excluded. Appendix 1 is a checklist for use by the clinician to abide by the
inclusion/exclusion criteria.
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Exclusion criteria will include any patients younger than 18 years old. A tinnitus
described as “pulsatile” or “clicking” will be excluded. Additionally, any previous or current use
of tinnitus treatment, including, but not limited to, antioxidants, antidepressants, melatonin, TRT
or CBT, will be cause for exclusion. The patient must also complete the informed consent form,
if the patient refuses, s/he will be excluded from the study.
Further audiologic exclusion criteria include abnormal otoscopic evaluation, including
perforated tympanic membrane or a mass observed through the tympanic membrane. Patients
with active middle ear disease or conductive hearing loss are excluded, including abnormal
tympanograms classified as Type B, meaning no peak due to perforation, effusion, or otherwise.
Additionally, any confirmed retrocochlear pathology (e.g. acoustic neuroma) or diagnosis of
Meniere’s Disease will be cause for exclusion. Lastly, any treatment with aminoglycoside
antibiotics, platinum-based chemotherapy, quinine, or otherwise ototoxic medication will lead to
exclusion from the study. As seen in Baguley, McFerran, and Hall (2013), the above mentioned
otologic findings can be accompanied by tinnitus, which may or may not resolve with treatment.
A patient with impacted cerumen upon otoscopy will be excluded from the study if the tinnitus
resolves after cerumen removal, otherwise they will be included. Patients with any of the above
will be excluded from the current study to minimize confounding factors.
After approval by the International Review Board (IRB) at the City University of New
York (CUNY), the pharmacist employed at the International Hearing Centre in Lagos, Nigeria
indicated to the researchers a lack of consistent charting for the NH tinnitus patients. The
redacted charts received by the researchers included audiograms, general case history forms, and
a formal report by the lead audiologist. However, a majority of the charts did not include a preadministration tinnitus questionnaire or any follow-up visit questionnaires. Due to the
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inconsistent charting and lack of protocol for tinnitus patient charts, this Capstone project will
propose an evidence-based guideline for audiologists and pharmacists to follow at the IHC, as
well as, for future use by clinicians and healthcare professionals involved with the administration
of the NH nutraceutical formulation.
The case history form (Appendix 2) to be used for future patients to whom the NH
formula will be administered must contain the following information, suggested by the American
Speech-Language-Hearing Association (n.d.), completed by the Audiologist and patient at the
initial visit:
•

Tinnitus description -- the patient will be asked to describe their tinnitus in the following
ways:
o

Presentation - referring to a description such as a ring, buzz, click, hiss, heartbeat,
chirp, or any other sound it may be akin to.

o

Onset and duration of the tinnitus

o

Pitch - patient may describe as high- or low-pitch, or relate it to a household
sound

o

Loudness - patient can confirm if the tinnitus is louder than conversation, noticed
only in the quiet of the home, or otherwise

o

Maskability – an account of any sounds or activities that dampen the tinnitus

•

Medical history – other diagnoses and lab results from other health professionals

•

Provoking and alleviating factors for tinnitus percept

•

History of noise exposure or trauma

•

Otologic or vestibular issues
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•

Other concerns including anxiety and depression - A patient scoring greater than 36 on
the THI will be administered the Beck Anxiety Inventory (BAI) -- a 21-item
questionnaire used in the clinical setting to measure anxiety levels in adolescents and
adults. A score > 16 on the BAI signifies a moderate level of anxiety or greater and will
lead to referral to a medical professional, i.e. psychiatrist or clinical psychologist (Grant,
2011; Biesinger et al. 2011). Salviati et al. (2013) determined a score greater than 36
points on the THI was correlated with a psychiatric disorder in tinnitus patients. Almost
half of the tinnitus patients in their study were found to have either anxiety disorder,
adjustment disorder, bipolar disorder, or other mental health disorders (Salviati et al.,
2013).

At the initial visit, audiometric data must include the following objective and subjective test
measures:
•

Pure tone air conduction thresholds: Octave frequencies 250-8000Hz and
interoctave frequencies 3000 and 6000Hz. Langguth et al. (2007) state pure tone
audiometry up to 8kHz is necessary for all patients, with recommendations of high
frequency audiometry (HFA) thresholds up to 12kHz. In studies of noise induced hearing
loss, the highest percentage of hearing loss is present between 3000 and 8000 Hz,
including 6000Hz (Hwang et al., 2009). For this reason, 3000 and 6000 Hz will be
included in audiologic assessment, due to the close link between noise exposure, hearing
loss, and tinnitus. Interoctave frequencies between 500 and 2000Hz will be assessed only
if a difference of 20dB or more is present between adjacent frequencies (Schlauch and
Nelson, 2009). The IHC does not have the equipment necessary to perform high
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frequency audiometry, therefore, HFA will not be part of the recommended audiologic
evaluation.
•

Pure tone bone conduction thresholds: Octave frequencies 500-4000Hz - unmasked
bone conduction thresholds will be measured at the four octave frequencies between .54kHz. An air-bone gap of more than 10dB will require masking to determine the nature
of the hearing loss (Schlauch and Nelson, 2009).

•

Immittance results: Rosowski and Wilber (2015) recommend 226 Hz tympanograms as
determined by the ANSI S3.36 standard; ipsilateral and contralateral acoustic reflex
thresholds (ARTs) measured at 500, 1000, and 2000 Hz in 5 dB steps with a 0.02 mmho
stimulus-related immittance change [4000 Hz will not be assessed as ARTs at this
frequency are often elevated (Gelfand, 2009)]; and reflex decay measured at 500Hz for
10 seconds at 10dB SL above the ART in the contralateral stimulus mode (Gelfand,
2009).

•

Distortion product otoacoustic emissions results - 1.5-12kHz - Langguth et al. (2007)
recommend OAEs as part of the audiologic assessment. Since HFA is not possible at
IHC, DPOAE results up to 12kHz will be implemented as part of the proposed protocol
to assess cochlear outer hair cell function in the ultra-high frequencies.

The audiological evaluation will be completed at 6-months and 1-year post-initial administration
of the NH formula to measure stability of hearing levels. Any significant decreases in auditory
thresholds (15 dB HL or more) will result in temporary cessation of the NH formula, until
medically cleared by an otolaryngologist. Haase et al. (2011) report the formulation to have
neuroprotective properties, and deny any adverse side effects due to toxicity. The NH formula,
as mentioned, has a specified dosing schedule meant to maintain antioxidant levels in the blood
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at safe levels. As in other research of ototoxic medications, cessation of therapy is indicated if
significant health changes occur (e.g. changes in hearing), therefore, the recommendation for the
clinical protocol at the IHC is to regularly monitor hearing thresholds and to stop use of the
nutraceutical if any significant changes are noted (Wilcox and Artz, 2007).
The Tinnitus Handicap Inventory (THI), seen in Appendix 3, must be filled out by the
patient at the first visit to determine the severity of tinnitus. Additional questions that may be
included for informational purposes will be answered with yes, sometimes, or no. The final
question will be answered with a percentage score. See the following:
•

My tinnitus has led me to avoid social situations (Wilson et al., 1991)

•

My tinnitus has led me to think about suicide (Wilson et al., 1991)

•

My tinnitus contributes to a feeling of general ill health (Kuk et al., 1990)

•

I have a healthy outlook on tinnitus (Kuk et al., 1990)

•

I have support from my friends and family regarding my tinnitus (Kuk et al., 1990)

•

What percentage of your time awake were you consciously aware of your tinnitus?
(Meikle et al., 2012)

The THI and additional questions will then be re-administered at the 3-month, 6-month, 9-month
and 1-year follow up visits. In other studies of antioxidant usage for treatment and maintenance
of disease, researchers followed up with patients every three months to monitor status. For
example, Gutzmann and Hadler (1998) and Weyer et al. (1997) followed patients with
Alzheimer’s Disease for two years with follow up visits every 3 months to reassess results on the
Alzheimer’s Disease Assessment Scale (ADAS), the Mini-Mental State Evaluation (MMSE) and
the Digit Symbol Substitution Test (DSS).
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RESULTS
Pre-treatment and 1-year post-treatment audiologic results will be compared in a table
including pure tone audiometric thresholds, distortion product otoacoustic emission results,
tympanometry and acoustic reflex testing. It is important to note, although the patient will have
had an audiologic evaluation at the 6-month interval, post-treatment, the results section will only
assess the 1-year post-treatment results. The purpose of the research is to assess the clinical
implications of the NH formula on tinnitus perception. Audiologic evaluations at 6-month
intervals are explicitly for monitoring hearing status in patients taking the formula. As
previously indicated in ototoxic drug administration research, it is important to monitor stability
of auditory thresholds and cease therapy if adverse health changes occur (Wilcox and Artz,
2007). Here, any significant decrease in auditory thresholds of 15 dB HL or more will be cause
for temporary cessation of antioxidant therapy until medically cleared by an otolaryngologist.
The primary outcome measure will be the THI, which will be administered at 3-month
intervals. The THI score will be compared to the baseline, pre-treatment score at each interval.
The use of pre-administration and post-administration questionnaires allows for each patient to
serve as their own control. The hypothesized expectation is a statistically significant
improvement in THI score and subjective improvement in tinnitus percept to the patient after 1year of NH administration. The null hypothesis is no improvement in THI score or subjective
improvement after 1-year NH administration. The research will aim to assess if the results at 3-,
6-, 9-months, and 1-year post-administration have a cumulative effect, suggesting the percept
continues to decrease in severity to the patient; or if there is a ceiling effect to the treatment that
will plateau at a point in time.
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Statistical analysis will be used to determine any differences in pre- and postadministration THI scores. Clinical significance, as discovered by Zeman et al., is defined as a
change in the THI of 7 points or greater (2011). For comparison of serial measurements, i.e.
before and after, within patients, the non-parametric Wilcoxon Signed Ranks Test will be
used. Statistical significance will be defined as a p-value < 0.05.
The research outcomes will also be analyzed for any significant differences between
subjects. Of particular interest could be age, gender, or description of tinnitus percept. To assess
any between-subjects results, the researchers would use an independent samples / unpaired ttest. Age may be divided into an older and younger group in order to make the analysis. These
groups may be determined once participants have been identified. The tinnitus percepts, too,
may be separated into groups dependent on patient reports. Statistical significance, again, will
be determined with a p-value < 0.05.
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DISCUSSION
Implementing a clinical protocol for dispensing the NH formulation to patients reporting
subjective tinnitus is necessary to provide an evidence-based guideline for clinicians at the IHC.
Such guidelines could serve to improve patient care and create a uniform evaluation of tinnitus
patients. The anecdotal reports of clinicians and pharmacists at the IHC indicate subjective
improvement in tinnitus severity for patients suffering from tinnitus. A mandated clinical
protocol will allow patients to receive the same standard of care, as well as allow researchers to
quantitatively assess this particular management strategy. The present research evaluated a
systematic review of clinical practice guidelines for Denmark, Germany, the Netherlands,
Sweden, and the United States “Different teams, same conclusions,” “Clinical practice guideline
for diagnosis and treatment of chronic tinnitus in Japan,” and “Clinical practice
guideline: Tinnitus,” (Fuller et al., 2017; Ogawa et al., 2020; Tunkel et al., 2014). Additionally,
the Tinnitus Research Initiative lends a flowchart for patient management to be implemented on
an international level (Biesinger, 2011). Across the diverse guidelines, the most common
recommendations were highlighted in this project: a comprehensive evaluation including pure
tone air and bone audiometry, acoustic reflex thresholds and reflex decay, speech reception
thresholds, word recognition scores, and tympanometry; a complete case history to determine
onset and duration of tinnitus, description of tinnitus percept, how bothersome it is to the patient,
and the ability to mask the tinnitus; a completed Tinnitus Handicap Inventory and Beck Anxiety
Inventory (if indicated); and evaluation by an otolaryngologist if case history or audiological
evaluation indicate.
According to Murad (2017), clinical practice guidelines can assist clinicians in making
appropriate decisions in regards to patient assessment and management. One of the most
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important benefits of using systematically reviewed guidelines, such as the “Clinical practice
guideline: Tinnitus,” is improved patient care. Murad reports guidelines aim to encourage
proven interventions and discourage ineffective ones, thereby improving quality of care
(2017). He further posits guidelines can lessen disparities and reduce unnecessary variations in
care. It is important to recall the heterogeneity in chronic tinnitus patients. Clinical practice
guidelines help to introduce an evidence-based standard of care across the field created by
professionals who have considered the benefits and risks of diagnostic measures and
management techniques. Therefore, the protocol proposed to the IHC for use with their tinnitus
patients is meant to create a consistent level of quality care by the healthcare professionals. The
protocol aims to implement consistent charting efforts to aid in differential diagnosis and
outcome measurement. For instance, the current charting contained incomplete tinnitus
questionnaires and scant case history responses. With the complete aforementioned information,
the current study could have analyzed the tinnitus questionnaires pre- and post-administration of
the NH nutraceutical to investigate if the anecdotal reports of patients and clinicians equated to
clinically significant improvements. Although the consensus across published clinical practice
guidelines is negative toward dietary supplements and nutraceutical formulations, Woolf et al.
(1999) reminds us of some limitations to guidelines. They suggest only a small number of
studies are well-designed with good generalizability. The evidence is sometimes lacking or
misinterpreted. Therefore, and perhaps ironically, it is imminent the IHC implements consistent
charting so research may analyze the outcomes of the NH nutraceutical and its seemingly
positive effects on chronic tinnitus patients.
Research indicates positive outcomes in tinnitus resolution when the primary disease is
treated. For instance, in cases of tinnitus secondary to cerumen impaction, otitis media, or
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temporomandibular joint disorder, removal of cerumen, antibiotics, or neuromuscular splints
have shown improvement in subjective tinnitus, respectively (Attanasio et al., 2015; Baguley et
al., 2013). However, in cases of acoustic neuroma patients, subjective tinnitus improved in 16%
of patients and worsened in 29% of patients after resection of the tumor (Fahy et al., 2002).
Additionally, tinnitus symptoms secondary to ototoxic drug administration have been shown to
reduce in severity with drug cessation (Attanasio et al., 2015). The current study aims to
implement clinical practice guidelines at the IHC, where health professionals have taken a
therapeutic approach to tinnitus with uncertain etiology. Elgoyhen and Langguth (2011)
mention, there is an unmet need for a drug therapy aiming to eliminate, or at the very least, to
produce a small, but significant change to the tinnitus percept. The NH formula, described by
Haase et al. (2011) as the HH formula, provides a broad spectrum of antioxidants and their
derivatives combined to impact oxidative damage and inflammation and to provide
neuroprotection in hearing disorders. Previous research of antioxidants and tinnitus has revealed
contradictory findings. As previously reviewed, the most efficacious pharmacotherapies, thus
far, have been those combating comorbidities such as insomnia, depression, and anxiety. Here,
the NH formula incorporates a comprehensive, multiple micronutrient strategy, rather than the
single, limited combination approaches used in the past. Therefore, controlled clinical research
must be completed to investigate the proposed benefits of the NH formula. Furthermore, a
complete, clinical protocol needs to be implemented to allow for this research. The implications
of positive findings secondary to the proper use of the NH formula are tinnitus relief for sufferers
of chronic tinnitus and limited side effects. Some previous drug therapies that have had adverse
side effects include: anti-epileptic drugs, benzodiazepines, intratympanic gentamicin and steroid
injections, lidocaine, and vasodilators (Smith, Zheng & Darlington, 2005). Additionally, Ginkgo
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biloba, particularly when taken with drugs like aspirin, can increase the risk of bleeding due to
its vasodilatory effects (Smith, Zheng & Darlington, 2005). Haase et al. (2011) reviewed the
dosage of the ingredients in the NH, formerly HH, formula. Toxicity was reported in Vitamins
A and D and the mineral selenium at high doses; however, the dosage in the NH formula is
below levels associated with adverse side effects. The remaining ingredients are all considered
to be non-toxic (Haase et al., 2011). Thus, the nutraceutical formulation has the ability to be a
positive incorporation into the tinnitus management portfolio for clinicians. The benefits
outweigh the risks of the NH formula and as Elgoyhen and Langguth (2010) mention, patients
are desperate for a drug therapy that could reduce or completely stop this subjective sound.
This desperation has led patients to search tirelessly for treatments, both medicinal and
behavioral, that can help alleviate the negative associations brought on by the tinnitus.
According to the IHC in Lagos, Nigeria, patients have reported subjective benefit to tinnitus
perception associated with taking the NH formula. This has placed a high demand on the
nutraceutical. Even though the nutraceutical sells for 14,000 Naira (N14,000), patients will
come from distant states or neighboring countries, as far as eighteen hours’ drive, to acquire the
formulation (I. Okeke, personal communication, January 20, 2020). This amounts to about $40
according to the most current exchange rates (XE Currency Converter, 2020). However, it does
not take into account the cost of living and salary differential between the United States and
Nigeria. The average Nigerian monthly salary, according to Trading Economics (2018) is about
N43,000, while the average American monthly salary is about $3600, according to the Bureau of
Labor Statistics (2020). Therefore, if one bottle of NH costs N14,000, this is about ⅓ of the
average Nigerian’s monthly salary, which then amounts to almost $1200, ⅓ of the average
American’s salary, for one bottle, or one month’s supply. The distance traveled and the cost
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paid, in tandem, lend themselves as strong indicators that this nutraceutical is helping patients to
deal with a chronic problem. Unfortunately, there is no health insurance system in place that
covers the cost of a supplement such as NH, nor does one exist that covers the cost of diagnostic
evaluations.
There is currently a dysfunctional health insurance system in Nigeria called the Nigerian
Health Insurance Scheme (NHIS). Created about 10 years ago, the NHIS attempted to provide
prepayment plans to Nigerian citizens (Nsofor, 2018). According to Okpani and Abimbola
(2015), only about 5% of Nigerians have prepaid healthcare through social and voluntary private
insurance; an additional 20% of Nigerians receive healthcare through the federal government if
they are federal employees or the family members of federal employees; and the remaining 70%
of Nigerians are uninsured and pay out of pocket for healthcare. They further explain: public
sector healthcare facilities in Nigeria are located in each of the 36 states and are considered notfor-profit organizations. Even though the cost is significantly less than private sector facilities,
Okpani and Abimbola note a perception of poorer quality care in the public sector facilities
(2015). The IHC is considered part of the private sector health facilities and sees a majority of
its patients paying out of pocket. The cost, according to Dr. Okeke, founder and lead audiologist
at the IHC, for a basic hearing evaluation including pure tone air conduction and bone
conduction thresholds, speech reception thresholds, word recognition scores, and tympanometry
including acoustic reflex thresholds, is N14,000 (I. Okeke, personal communication, January 20,
2020).
The IHC and other healthcare facilities and practitioners are regulated by the Nigerian
government. Okpani and Abimbola (2015) explain the structure and responsibilities of the
government as it pertains to healthcare and pharmaceuticals. The government is separated into
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three branches: federal, state, and local. Of note, the federal government provides support to
state and local government on health program planning and implementation, health policy
making and priority setting, and setting minimum standards for training and licensing of health
workers. The Federal Ministry of Health (FMOH) notably regulates activities of healthcare
practitioner groups and regulates pharmaceutical and food products. The NHIS, an agency of the
FMOH, regulates healthcare and accredits HMOs.
A separate entity from the federal government is the National Agency for Food and Drug
Administration and Control (NAFDAC). The NAFDAC, similar to the United States Food and
Drug Administration (FDA), imposes guidelines on food, drugs, medical devices, herbals and
cosmetics, among other items (NAFDAC, 2016). According to Dr. Okeke, the registration
process for proper licensing and distribution of the NH nutraceutical formulation requires
compliance with several directives: evidence and scientific studies of NH, inspection of the
manufacturer’s location, and presence of a superintendent pharmacist for dispensation of the
nutraceutical (I. Okeke, personal communication, January 20, 2020). The professional role of
pharmacists in Nigeria has evolved from a focus on preparation, dispensing, and sale of
medications to one where the pharmacists are present to assist the public in education and patient
monitoring for the best possible results (Erah, 2003). Therefore, the role of the pharmacist at the
IHC helps to ensure proper protocol in dispensing the NH formula for all patients seen. The
above evidence of patients traveling from afar and paying up to ⅓ their salary to obtain the NH
nutraceutical is important to remember when considering perceived benefit from the formula. It
appears there is a benefit that far outweighs the cost and accessibility.
A recent randomized, single-blind clinical trial by Petridou et al. (2019) assessed the use
of antioxidant supplementation in a group of chronic tinnitus sufferers compared to matched
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placebo controls in Greece. Although the authors do not name the supplement, the ingredient
list, found in Appendix 4, is very similar to that of NH. The study added a supplement of alphalipoic acid (ALA) to participants' daily intake, which is also found in the proprietary formula of
NH. Participants were followed for three months, assessing pre-treatment and post-treatment
results on pure tone audiometry 250-12,000Hz, pitch and loudness psychoacoustic matching
measurements, and three questionnaires: THI, Tinnitus Functional Index (TFI), and the visual
analogue scale (VAS) for tinnitus disturbance. After three months, the antioxidant group was
found to have significantly lower scores on THI, VAS, and TFI compared to the placebo group.
This, the authors suggest, means the antioxidant supplementation was effective in alleviating
patients from tinnitus-related distress compared to the placebo group. It is promising to see a
formula with a similar list of ingredients has proven effective in a well-designed clinical trial.
In October 2019, a press release from New Age Beverages Corporation announced the
launch of the NH formula in Japan, following a test-market release in Korea (New Age
Beverages Corporation, 2019). It appears Japan does have a regulatory body, similar to the U.S.
FDA, called the Pharmaceutical and Food Safety Bureau (PFSB), which is part of the larger
Ministry of Health and Welfare (MHW) (Nagata & Rafizadeh-Kabe, 2002). The PFSB,
according to Nagata and Rafizadeh-Kabe, is responsible for approval review and regulation and
decision-making for the MHW (2002). On the report of the authors, western medicines are seen
as potentially dangerous by the Japanese public. This indicates there may be some positive
outcomes derived in clinical trials that have encouraged the public to adopt the NH formula for
tinnitus management.
For patients suffering from bothersome, chronic tinnitus, a combination of the NH
antioxidant nutraceutical with another form of therapy may also prove efficacious. For example,
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the addition of tinnitus retraining therapy may help to combine a central auditory therapy with
the peripheral auditory therapy of the nutraceutical. Of the many theories surrounding the
pathophysiology of tinnitus, one that has continued to be particularly interesting is the
involvement of the limbic system. Rather than a peripheral auditory system dysfunction, limbic
system involvement proposes central dysfunction. Michel et al. (2015) suggest the limbic
system has an important role in learning and memory function, as well as generation, integration,
and control of emotions and behavioral responses. It seems reasonable that a system involved
with behavioral responses has an effect on a patient’s awareness and disturbance by this phantom
auditory percept. Michel et al. explain further the dysfunction of the limbic regions are
implicated in etiology of mental disorders like anxiety and depression (2015). The link between
chronic tinnitus and anxiety or depressive symptoms has been repeatedly investigated, and in
their 2018 systematic review and meta-analysis, Trevis, McLachlan, and Wilson found 64% and
62% of studies investigating depression and anxiety showed a significant increase in depressive
or anxiety symptoms in chronic tinnitus sufferers compared to healthy controls, respectively.
Consequently, a positive association between limbic system dysfunction and chronic tinnitus
may be present. This migrates the focus away from a wholly peripheral auditory dysfunction and
allows the introduction of central factors.
Other studies of limbic system involvement in chronic tinnitus examined brain imaging in
tinnitus patients and healthy controls. Leaver et al. (2012) discovered reduced grey matter
volume in the ventromedial prefrontal cortex (vmPFC), which has also been linked to depression
and anxiety. They suggest this causes a failure to suppress aberrant activity in the auditory
system. Additionally, Besteher et al. (2019) report grey matter alterations in tinnitus patients are
highly influenced by comorbid psychiatric disorders. They implicate the parahippocampal
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cortex in memory mechanisms related to phantom percept persistence. A 2011 study by Leaver
et al. also found robust differences between chronic tinnitus patients and healthy controls in
limbic areas. Specifically, they point to reduced grey matter volume in the vmPFC and
hyperactivity in the nucleus accumbens (NAc). They suggest chronic tinnitus is caused by a
compromised limbic corticostriatal circuit. This lends itself to a “disordered evaluation of the
tinnitus sensation’s perceptual relevance and an increased gain control of the percept” (p. 37). In
other words, the dysfunctional system has difficulty determining which sensations are important
and how they are experienced, making the sound perhaps perceptually louder than if measured in
decibels.
Jastreboff and Jastreboff (2001) indicate TRT avoids further excitation of the limbic
system to prevent changing the tinnitus signal. The aim is not to mask the signal, but rather to
allow the patient to habituate. They further suggest a sound therapy that enhances the activation
of the limbic system will enhance the tinnitus annoyance. TRT combines interactive teaching
and counseling sessions with sound use that is significantly above the threshold of tinnitus
perception. In the case of introducing a nutraceutical formulation, the percept, in theory, will
gradually decrease as the patient follows the proper dosing schedule. TRT will continue to use
sound that limits activation of the limbic system, but the threshold above tinnitus perception will,
again in theory, decrease as the peripheral and central auditory systems improve.

35

CONCLUSION
Initially this project sought to investigate patient records from the International Hearing
Centre in Lagos, Nigeria after learning patients reported subjective improvement in bothersome
tinnitus. Incomplete charting transformed this research into a review of clinical practice
guidelines for diagnostic evaluation and suggested timelines for assessing subjective validation
measures of change to the tinnitus, i.e. the Tinnitus Handicap Inventory. The goal of this project
is to implement an evidence-based clinical protocol at the IHC to standardize patient care in
order to evaluate and statistically analyze the efficacy of the NH formulation on subjective
tinnitus sufferers in the future. Future research can use this project as a template to assess
changes to tinnitus percept in patients taking the NH formulation.
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Appendix 1
Inclusion/Exclusion Checklist
For use by the clinician

Characteristics

Responses

Necessary Response for
Inclusion

18 years of age or older

YES/NO

YES

Chronic tinnitus for 6 months or more

YES/NO

YES

Pulsatile or clicking tinnitus?

YES/NO

NO

Taken NH for 3 months or more?

YES/NO

YES

Current or previous use of other tinnitus
treatment?

YES/NO

NO

Tinnitus resolved after cerumen removal?

YES/NO

NO

Perforated tympanic membrane?

YES/NO

NO

Mass observed behind the tympanic
membrane?

YES/NO

NO

Type B tympanograms?

YES/NO

NO

Conductive hearing loss or active middle ear
disease?

YES/NO

NO

Retrocochlear pathology?

YES/NO

NO

Meniere’s Disease?

YES/NO

NO

Use of ototoxic medications?

YES/NO

NO
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Appendix 2
Case History Form
Age ________________________
Gender _____________________
Occupation __________________
Medical History (mark “X” to all that apply)
___Diabetes
___Hypertension
___Cancer (if yes, please specify __________________)
___Chemotherapy
___Temporomandibular Disorder (TMJ)
___Ear surgery
___Heart problems (please specify _________________)
___Kidney disease
___Thyroid disorder
___Autoimmune disease
___HIV/AIDS
___Head or neck trauma
___Depression, anxiety, sleep disorder
___Other (please specify _________________________)
Please list all medications you are currently taking:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Any history of recreational or occupational noise exposure?
______________________________________________________________________________
______________________________________________________________________________
Any history of hearing loss, ear issues, or vestibular/balance disorder?
______________________________________________________________________________
Tinnitus History
1. What does it sound like? (e.g. buzz, click, ring, hiss, chirp, other) _______________
2. When did it begin? ____________________________________________________
3. How often does it occur? (e.g. intermittent, constant) _________________________
4. What pitch is the tinnitus? (e.g. high, low, mid) _____________________________
5. How loud is the tinnitus? (e.g. louder than conversation, only in quiet, other)______
_______________________________________________________________________
6. Do any sounds effectively mask the tinnitus? _______________________________
7. Does anything provoke or exacerbate the tinnitus? ___________________________
________________________________________________________________________
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8.
9.

Does anything alleviate the tinnitus? ______________________________________
Does the tinnitus stop you from performing daily activities? ___________________

Answer the following questions with yes, sometimes, or no:
1. My tinnitus has led me to avoid social situations ____________________________
2. My tinnitus has led me to think about suicide _______________________________
3. My tinnitus contributes to a feeling of general ill health _______________________
4. I have a healthy outlook on tinnitus _______________________________________
5. I have support from my friends and family regarding my tinnitus _______________
What percentage of your time awake are you consciously aware of your tinnitus? ____________
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Appendix 3
Tinnitus Handicap Inventory (Newman et al., 1996)
1. Because of your tinnitus, is it difficult for you to concentrate? Yes (4) Sometimes (2) No
(0)
2. Does the loudness of your tinnitus make it difficult for you to hear people? Yes (4)
Sometimes (2) No (0)
3. Does your tinnitus make you angry? Yes (4) Sometimes (2) No (0)
4. Does your tinnitus make you feel confused? Yes (4) Sometimes (2) No (0)
5. Because of your tinnitus, do you feel desperate? Yes (4) Sometimes (2) No (0)
6. Do you complain a great deal about your tinnitus? Yes (4) Sometimes (2) No (0)
7. Because of your tinnitus, do you have trouble falling asleep at night? Yes (4) Sometimes
(2) No (0)
8. Do you feel as though you cannot escape your tinnitus? Yes (4) Sometimes (2) No (0)
9. Does your tinnitus interfere with your ability to enjoy your social activities (such as
going out to dinner, to the movies)? Yes (4) Sometimes (2) No (0)
10. Because of your tinnitus, do you feel frustrated? Yes (4) Sometimes (2) No (0)
11. Because of your tinnitus, do you feel that you have a terrible disease? Yes (4) Sometimes
(2) No (0)
12. Does your tinnitus make it difficult for you to enjoy life? Yes (4) Sometimes (2) No (0)
13. Does your tinnitus interfere with your job or household responsibilities? Yes (4)
Sometimes (2) No (0)
14. Because of your tinnitus, do you find that you are often irritable? Yes (4) Sometimes (2)
No (0)
15. Because of your tinnitus, is it difficult for you to read? Yes (4) Sometimes (2) No (0)
16. Does your tinnitus make you upset? Yes (4) Sometimes (2) No (0)
17. Do you feel that your tinnitus problem has placed stress on your relationships with
members of your family and friends? Yes (4) Sometimes (2) No (0)
18. Do you find it difficult to focus your attention away from your tinnitus and on other
things? Yes (4) Sometimes (2) No (0)
19. Do you feel that you have no control over your tinnitus? Yes (4) Sometimes (2) No (0)
20. Because of your tinnitus, do you often feel tired? Yes (4) Sometimes (2) No (0)
21. Because of your tinnitus, do you feel depressed? Yes (4) Sometimes (2) No (0)
22. Does your tinnitus make you feel anxious? Yes (4) Sometimes (2) No (0)
23. Do you feel that you can no longer cope with your tinnitus? Yes (4) Sometimes (2) No
(0)
24. Does your tinnitus get worse when you are under stress? Yes (4) Sometimes (2) No (0)
25. Does your tinnitus make you feel insecure? Yes (4) Sometimes (2) No (0)

The sum of all responses is your THI Score ________________
0-16 points – Slight or no handicap
18-36 points – Mild handicap
38-56 points – Moderate handicap
58-76 points – Severe handicap
78-100 points – Catastrophic handicap
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Appendix 4
Petridou et al (2019) Antioxidant Ingredients

Ingredient

Amount Per Serving

% Daily Value

Difference

Vitamin A

2600 IU

98%

~ half less than NH

Vitamin C

150 mg

188%

100mg less

Vitamin D3

400 IU

200%

*Vitamin D in NH

Vitamin E

150 IU

833%

50IU less

Thiamin

25 mg

2272%

5x as much

Riboflavin

25 mg

1786%

5x as much

Niacin

25 mg

156%

Same

Vitamin B6

10 mg

714%

2x as much

Folic Acid

200 mcg

100%

Same

Vitamin B12

10 mcg

400%

Same

Biotin

150 mcg

300%

About half as much

Pantothenic Acid

25 mg

417%

2x as much

Calcium

62 mg

8%

Same

Iron

14mg

100%

Not found in NH

Magnesium

50 mg

13%

About half as much

Zinc

15 mg

150%

Same

Selenium

100 mcg

200%

Same

Chromium

200 mcg

500%

Almost 4x as much

Molybdenum

500 mcg

1000%

Not found in NH

Iodine

150 mcg

100%

Not found in NH

Choline, Inositol, PABA

25mg each

Not specified

Not found in NH

Grapeseed extract

500 mg

Not specified

Not found in NH
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